• Ramazan Gozukucuk and Hasan Huseyin Kilic.
• Ramazan Gozukucuk, Department of Infectious Disease and Clinical Microbiology, Faculty of Dentist, Istanbul Galata University, Evliya Çelebi, Meşrutiyet Cd. No:62, Beyoglu, Istanbul, 34430 Turkey. Hisar Hospital Intercontinental,Saray Mah. Siteyolu Cad.No:7, Umraniye, Istanbul, 34768 Turkey.
• Pak J Med Sci. 2023 Sep 1; 39 (5): 128612901286-1290.

ObjectiveTo examine the use of anti-cytokine treatment in critical COVID-19 patients and their association with the frequency of CMV cases, viral load level, and mortality in these patients.MethodsThis is a retrospective study. A total of 170 critical and/or intensive care patients with COVID-19 admitted to Hisar Hospital Intercontinental from March 15, 2020, to December 31, 2021 were divided into the use of anti-cytokine treatment group and the no anti-cytokine treatment group. Furthermore, the relationship between CMV reactivation, mortality and anti-cytokine treatment in patients was also examined.ResultsA total of 170 critical COVID-19 patients were included in the study, three of them were excluded. One hundred sixty seven were included in the study of which 38 (22.7%) were found to be CMV DNA positive. As an anti-cytokine treatment, it was observed that tocilizumab was used in 53 patients, anakinra was used in 27 patients, and no anti-cytokine treatment was used in 77 patients. CMV positivity in patients treated with anti-cytokines (31.11%) was found to be significantly higher than in patients who were not treated with it (16.88%) (p:0.033). Furthermore, it was determined that anti-cytokine treatment significantly decreased mortality (p: 0.003) and that there was no significant relationship between CMV reactivation and mortality (p: 0.399).ConclusionEven though CMV reactivation was high in critical COVID-19 patients who received anti-cytokine treatment, decrease in mortality were observed with early diagnosis and effective treatment. Therefore, CMV infection should be considered in patients receiving immunosuppressive treatment.Clinical Trial Registration: HisarIH-101/NCT05419206.Copyright: © Pakistan Journal of Medical Sciences.

6 keywords...

hide…